# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based th...
HC Wainwright & Co. analyst Edward White maintains GlycoMimetics (NASDAQ:GLYC) with a Buy and maintains $8 price target.
GlycoMimetics (NASDAQ:GLYC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15)...
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...